IVF Outcome, Stimulation in the Ovary
Conditions
Keywords
progesterone, premature ovulation, ovarian stimulation, luteal stimulation
Brief summary
There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.
Interventions
OTHEROvarian stimulation with menstruation or after ovulation
Ovarian stimulation with menstruation or after ovulation
Sponsors
ART Fertility Clinics LLC
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18 to 38 years old. * Normal Menstrual cycle of 25-35 days. * Body Weight 60to90 kg * AMH\>1.3 - \<3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of \>5 on menstrual cycle days 2-3,
Exclusion criteria
* History of premature ovulation * Azoospermia * PCOS * Endometriosis AFS ¾ * Endometrioma * Known chromosomal abnormalities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the Oocyte maturity, Fertilization rate, Blastulation rate, quality Euploidy rate, Premature ovulation rate, Number of injections used and costs | From enrollment to the end of treatment at 8 weeks |
Countries
United Arab Emirates
Contacts
CONTACTJonalyn Edades, EMBA
CONTACTBarbara Lawrenz, PhD
STUDY_DIRECTORBarbara Lawrenz, PhD
ART Fertility Clinics LLC
Outcome results
None listed